Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18239765 | 0.84 | PTGDR2 (0.48) | PTGDR2PTGDRMAPT | |
| SCHEMBL12255254 | 0.79 | PTGDR2 (0.52) | PTGDR2PTGDRAKR1C3 | |
| SCHEMBL2388026 | 0.78 | AKR1C3 (0.45) | AKR1C3AKR1C2MAPTTSHRLMNA | |
| SCHEMBL13228926 | 0.74 | PTGS2 (0.65) | PTGDR2PTGDRAKR1C3AKR1C2MAPT | |
| SCHEMBL2389675 | 0.74 | AKR1C3 (0.42) | AKR1C3AKR1C2TSHRKDM4ELMNA | |
| SCHEMBL1941149 | 0.74 | PTGDR2 (0.84) | PTGDR2TSHRKDM4EALDH1A1 | |
| SCHEMBL18239866 | 0.74 | PTGDR2 (0.43) | PTGDR2PTGDRMAPTMEN1KMT2A | |
| SCHEMBL18239709 | 0.73 | PTGDR2 (0.44) | PTGDR2PTGDRMAPTTSHRKDM4E | |
| SCHEMBL12255264 | 0.73 | PTGDR2 (0.42) | PTGDR2PTGDRAKR1C3TSHRCYP1A2 | |
| SCHEMBL2004522 | 0.72 | PTGDR2 (0.66) | PTGDR2PTGDRAKR1C3AKR1C2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481587-B2 | Substituted 2-(5-hydroxy-2-methyl-1H-indole-3-yl)acetic acids and ethers thereof and the use of same to treat viral diseases | IVASHCHENKO ANDREY ALEXANDROVICH (RU) | 2013-07-09 | — | — | US | disclosed |
| US-8481587-B2 | Substituted 2-(5-hydroxy-2-methyl-1H-indole-3-yl)acetic acids and ethers thereof and the use of same to treat viral diseases | IVASHCHENKO ANDREY ALEXANDROVICH (RU) | 2013-07-09 | — | — | US | disclosed |
| US-20110230524-A1 | SUBSTITUTED 2-(5-HYDROXY-2-METHYL-1H-INDOLE-3-YL)ACETIC ACIDS AND ETHERS THEREOF AND THE USE OF SAME TO TREAT VIRAL DISEASES | ALLA CHEM, LLC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230524-A1 | SUBSTITUTED 2-(5-HYDROXY-2-METHYL-1H-INDOLE-3-YL)ACETIC ACIDS AND ETHERS THEREOF AND THE USE OF SAME TO TREAT VIRAL DISEASES | ALLA CHEM, LLC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230524-A1 | SUBSTITUTED 2-(5-HYDROXY-2-METHYL-1H-INDOLE-3-YL)ACETIC ACIDS AND ETHERS THEREOF AND THE USE OF SAME TO TREAT VIRAL DISEASES | IDO1, TPH1, FOXM1 | PTGDR2 2499/4885PTGDR 2177/4885AKR1C3 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.